[Federal Register Volume 91, Number 25 (Friday, February 6, 2026)]
[Rules and Regulations]
[Pages 5291-5295]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-02314]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 73

[Docket No. FDA-2024-C-3384]


Listing of Color Additives Exempt From Certification; Spirulina 
Extract

AGENCY: Food and Drug Administration, HHS.

ACTION: Final amendment; order.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or we) is amending the 
color additive regulations to provide for the expanded use of spirulina 
(Arthrospira platensis) extract as a color additive in human foods 
generally (except for infant formula, certain foods subject to 
regulation by the U.S. Department of Agriculture, and foods for which 
standards of identity have been issued under section 401 of the Federal 
Food, Drug, and Cosmetic Act, unless the use of the added color is 
authorized by such standards) at levels consistent with good 
manufacturing practice (GMP), to lower the heavy metal specifications 
for lead, arsenic, and mercury, and to add a specification for cadmium. 
We are taking this action in response to a color additive petition 
(CAP) submitted by GNT USA, LLC (GNT or petitioner).

DATES: This order is effective March 23, 2026 See section IX of this 
document for further information on the filing of objections. Either 
electronic or written objections and requests for a hearing on the 
order must be submitted by March 9, 2026.

ADDRESSES: You may submit objections and requests for a hearing as 
follows. Please note that late, untimely filed objections will not be 
considered. The https://www.regulations.gov electronic filing system 
will accept objections until 11:59 p.m. Eastern Time at the end of 
March 9, 2026. Objections received by mail/hand delivery/courier (for 
written/paper submissions) will be considered timely if they are 
received on or before that date.

Electronic Submissions

    Submit electronic objections in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Objections submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your objection will be 
made public, you are solely responsible for ensuring that your 
objection does not include any confidential information that you or a 
third party may not wish to be posted, such as medical information, 
your or anyone else's Social Security number, or confidential business 
information, such as a manufacturing process. Please note that if you 
include your name, contact information, or other information that 
identifies you in the body of your objection, that information will be 
posted on https://www.regulations.gov.
     If you want to submit an objection with confidential 
information that you do not wish to be made available to the public, 
submit the objection as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper objections submitted to the Dockets 
Management Staff, FDA will post your objection, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2024-C-3384 for ``Listing of Color Additives Exempt from 
Certification; Spirulina Extract.'' Received objections, those filed in 
a timely manner (see ADDRESSES), will be placed in the docket and, 
except for those submitted as ``Confidential Submissions,'' publicly 
viewable at https://www.regulations.gov or at the Dockets Management 
Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
     Confidential Submissions--To submit an objection with 
confidential information that you do not wish to be made publicly 
available, submit your objections only as a written/paper submission. 
You should submit two copies total. One copy will include the 
information you claim to be confidential with a heading or cover note 
that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' We 
will review this copy, including the claimed confidential information, 
in our consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://

[[Page 5292]]

www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts, and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT: Marissa Santos, Office of Pre-Market 
Additive Safety, Human Foods Program, Food and Drug Administration, 
5001 Campus Dr., College Park, MD 20740, 240-402-8160 or Meridith L. 
Kelsch, Office of Policy, Regulations, and Information, Human Foods 
Program, Food and Drug Administration, 5001 Campus Dr., College Park, 
MD 20740, 240-402-2378.

SUPPLEMENTARY INFORMATION: 

I. Introduction

    In the Federal Register of August 5, 2024 (89 FR 63330), FDA 
announced that we filed a color additive petition (CAP 4C0334) 
submitted on behalf of GNT by Exponent, 1150 Connecticut Ave. NW, Suite 
1100, Washington, DC 20036. The petition proposed that FDA amend the 
color additive regulations in part 73 (21 CFR 73.530), ``Listing of 
Color Additives Exempt from Certification,'' to provide for the 
expanded safe use of spirulina extract as a color additive at levels 
consistent with GMP in human foods generally, excluding infant formula 
and certain foods subject to regulation by the U.S. Department of 
Agriculture (USDA).

II. Background

    Spirulina extract is approved under Sec.  73.530 for coloring 
confections (including candy and chewing gum), frostings, ice cream and 
frozen desserts (including non-dairy frozen dessert), dessert coatings 
and toppings, beverage mixes and powders, yogurts (including non-dairy 
yogurt alternatives), custards, puddings (including non-dairy 
puddings), cottage cheese, gelatin, breadcrumbs, ready-to-eat cereals 
(excluding extruded cereals), alcoholic beverages with less than 20 
percent alcohol-by-volume content, non-alcoholic beverages, seasoning 
mixes (unheated), salad dressings, condiments and sauces, dips, coating 
formulations applied to dietary supplement tablets and capsules, at 
levels consistent with GMP, and to seasonally color the shells of hard-
boiled eggs, except that it may not be used to color foods for which 
standards of identity have been issued under section 401 of the Federal 
Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 341), unless the use 
of the added color is authorized by such standards. Spirulina extract 
is exempt from certification under section 721(c) of the FD&C Act (21 
U.S.C. 379e(c)) because we previously determined that certification was 
not necessary for the protection of public health (78 FR 49117 at 
49119, August 13, 2013).
    The spirulina extract that is the subject of this final order is a 
blue-colored powder or liquid prepared by the water extraction and 
filtration of the dried biomass of A. platensis (also known as 
Spirulina platensis), an edible blue-green cyanobacterium. The 
extraction and filtration remove oil, oil soluble substances, and 
fibers. The color additive contains phycocyanins as the principal 
coloring components, and consists of proteins, carbohydrates, and 
minerals. Based on data and information provided in the petition on the 
identity, physical and chemical properties, manufacturing process, and 
composition of the color additive, we have determined that the color 
additive meets the current specifications for spirulina extract in 
Sec.  73.530 (Refs. 1 and 2). During the review of the petition, FDA 
noted that the specifications for heavy metals could be lowered based 
on the results of the petitioner's batch analyses, and a specification 
for cadmium should be added. These modifications to the heavy metal 
specifications would align with FDA's work to reduce dietary exposure 
to contaminants. Therefore, in addition to expanding the use of 
spirulina extract, the petitioner proposed to lower the heavy metal 
specifications for lead (<=0.2 mg/kg), arsenic (<=0.3 mg/kg), and 
mercury (<=0.1 mg/kg) that are currently in the regulation, and to add 
a specification for cadmium (<=0.3 mg/kg).
    There is no generally recognized as safe (GRAS) exception in the 
definition of a color additive in section 201(t) of the FD&C Act (21 
U.S.C. 321(t)), and, therefore, the intended use of a color additive 
requires our approval. However, we note that spirulina-based 
ingredients have been the subject of several GRAS notices (GRNs) 
reviewed by FDA (discussed in 78 FR 49117 at 49118). (Under section 
201(s) of the FD&C Act, a substance is GRAS, and excepted from the 
definition of a food additive, if it is generally recognized, among 
experts qualified by scientific training and experience to evaluate its 
safety, to be safe under the conditions of its intended use.) In 
particular, the spirulina substance that was the subject of GRN 000424 
is similar in chemical composition to the subject color additive, with 
phycocyanin content ranging from 42 to 47 percent (id.). If a substance 
imparts color to a food, it may be subject to regulation as a color 
additive even if its use is also considered GRAS.

III. Safety Evaluation

A. Determination of Safety

    Under section 721(b) of the FD&C Act (21 U.S.C. 379e(b)), a color 
additive may not be listed for a proposed use unless the data and other 
information available to FDA establish that the color additive is safe 
for that use. Our color additive regulations at 21 CFR 70.3(i) define 
``safe'' to mean that there is convincing evidence establishing with 
reasonable certainty that no harm will result from the intended use of 
the color additive.
    To determine whether a color additive is safe under the general 
safety clause, the FD&C Act requires FDA to conduct a fair evaluation 
of the available data and consider, among other relevant factors: (1) 
probable consumption of, or other relevant exposure from, the additive 
and of any substance formed in or on food, drugs, devices, or cosmetics 
because of the use of the additive; (2) cumulative effect, if any, of 
such additive in the diet of man or animals, taking into account 
chemically or pharmacologically related substance or substances in such 
diet; and (3) safety factors recognized by experts as appropriate for 
the use of animal experimentation data (see section 721(b)(5)(A)(i) 
through (iii) of the FD&C Act).
    As part of our safety evaluation to establish with reasonable 
certainty that a color additive is not harmful under its intended 
conditions of use, we consider the additive's manufacturing and 
stability, the projected human dietary exposure to the additive and any 
impurities resulting from the petitioned use of the additive, the 
additive's toxicological data, and other relevant information (such as 
published literature) available to us. We compare the estimated dietary 
exposure to the color additive from all sources to an acceptable daily 
intake (ADI) level established by toxicological data. The dietary 
exposure is estimated based on the amount of the color additive 
proposed for use in particular foods or drugs and on data regarding the 
amount consumed from all sources of the color additive. We commonly use 
the dietary exposure for the 90th percentile consumer of a color 
additive as a measure of high chronic dietary exposure.

B. Safety of the Petitioned Use of the Color Additive

    During our safety review of this petition (CAP 4C0334), we 
considered the estimated dietary exposure to

[[Page 5293]]

spirulina extract and c-phycocyanin (the main coloring component) from 
the petitioned uses of the subject color additive. Specifically, the 
petition sought to expand the intended uses of this color additive to 
include all foods, except infant formula and certain foods subject to 
regulation by the USDA (i.e., products subject to regulation by the 
USDA under the Federal Meat Inspection Act (21 U.S.C. 601 et seq.), the 
Poultry Products Inspection Act (21 U.S.C. 451 et seq.), or the Egg 
Products Inspection Act (21 U.S.C. 1031 et seq.)). C-phycocyanin is the 
predominant phycocyanin present in spirulina, although low levels of 
allophycocyanin are also present; due to the predominance of c-
phycocyanin, the concentration of c-phycocyanin in spirulina extract is 
assumed to represent all ``phycocyanins'' in spirulina. The petitioner 
provided the eaters-only 90th percentile dietary exposure to spirulina 
extract and c-phycocyanin from the petitioned uses for the U.S. 
population aged 2 years and older, and various subpopulations.
    The petitioner provided information on the proposed expanded food 
uses of spirulina extract, including food categories in which spirulina 
extract is intended to be used and the corresponding maximum use levels 
that represent GMP for the petitioned uses (Ref. 2). The petitioner 
used food consumption data from the combined 2015-2016 and 2017-2018 
National Health and Nutrition Examination Survey (NHANES) to estimate 
the dietary exposure to spirulina extract from the petitioned uses. The 
petitioner estimated the eaters-only (i.e., only those individuals in 
the population that consume the foods of interest) dietary exposure to 
spirulina extract from the petitioned uses to be 6.3 grams/person/day 
(g/p/d) at the mean and 14.1 g/p/d at the 90th percentile for the U.S. 
population aged 2 years and older; and 5.1 g/p/d at the mean and 10.7 
g/p/d at the 90th percentile for children aged 2-5 years (Ref. 2). We 
independently confirmed the petitioner's dietary exposure using food 
consumption data from the combined 2015-2016 and 2017-2018 NHANES and 
concur with the petitioner's dietary exposure to spirulina extract 
(Ref. 2).
    The petitioner also estimated the eaters-only dietary exposure to 
c-phycocyanin from the petitioned uses of spirulina extract to be 0.13 
g/p/d at the mean and 0.28 g/p/d at the 90th percentile for the U.S. 
population aged 2 years and older; and 0.1 g/p/d at the mean and 0.21 
g/p/d at the 90th percentile for children aged 2-5 years (Ref. 2).
    The petitioner did not provide an updated cumulative dietary 
exposure estimate for c-phycocyanin in this petition. However, the 
petitioner indicated that: (1) the overall maximum GMP use level in the 
current petition is comparable to that in GRN 000424 on a c-phycocyanin 
basis; GRN 000424 pertains to the use of a spirulina-based substance 
similar in chemical composition to the subject color additive, but with 
a higher phycocyanin content; GRN 000424 pertains to the intended use 
in all foods (except infant formula and foods under the USDA's 
jurisdiction) (i.e., products subject to regulation by the USDA under 
the Federal Meat Inspection Act, the Poultry Products Inspection Act, 
or the Egg Products Inspection Act) at levels consistent with GMP; (2) 
the petitioner's spirulina extract would not be added to foods already 
containing other sources of spirulina; (3) the number of servings in 
the daily diet that could be colored with spirulina extract would 
reasonably be well below the assumption of 50% of the daily servings in 
the current cumulative dietary exposure of 1.14 g/p/d from the notified 
GRAS uses of spirulina; and (4) the current cumulative dietary exposure 
for c-phycocyanin is inclusive of the dietary exposure to c-phycocyanin 
from the approved uses of spirulina extract as a color additive under 
Sec.  73.530 as well as the expanded uses in the current petition. As 
such, the petitioner concluded that the intended uses of spirulina 
extract in this petition would be substitutional to other sources of 
spirulina in foods (on a c-phycocyanin basis), and the dietary exposure 
to c-phycocyanin from the petitioned uses would be subsumed by the 
dietary exposure to c-phycocyanin from the uses in GRN 000424. 
Therefore, the petitioned uses would not increase the current upper-
bound cumulative dietary exposure to c-phycocyanin of 1.14 g/p/d in GRN 
000424. We concur with the petitioner's statement regarding the 
cumulative dietary exposure to c-phycocyanin (Ref. 2).
    To support the safety of the petitioned use of spirulina extract, 
the petitioner referenced the safety determinations made by FDA for 
spirulina extract in CAPs 2C0293 (78 FR 49117, August 13, 2013), 2C0297 
(79 FR 20095, April 11, 2014), 4C0300 (80 FR 50762, August 21, 2015), 
6C0306 (82 FR 30731, July 3, 2017), and 0C0316 (87 FR 67785, November 
10, 2022). The petitioner also conducted an updated search of the peer-
reviewed scientific literature on spirulina and submitted the published 
studies that they identified as being relevant to their petition. The 
petitioner concluded that these publications did not reveal any 
significant new toxicological effects and should not alter the 
conclusion of FDA's previous reviews on spirulina.
    FDA's most recent evaluation of the use of spirulina extract as a 
color additive in alcoholic beverages with less than 20 percent 
alcohol-by-volume content, non-alcoholic beverages, condiments and 
sauces, dips, dairy product alternatives (non-dairy yogurt 
alternatives, non-dairy frozen desserts, and non-dairy puddings), salad 
dressings, and unheated seasoning mixes (87 FR 67785, November 10, 
2022), included a comprehensive review of studies submitted by the 
petitioner and a review of all available literature. From our 
evaluation, we did not have any concerns regarding the safety of the 
use of spirulina extract and its principal coloring components, 
phycocyanins.
    Of the publications submitted by the petitioner, some studies had 
been previously reviewed by FDA (Ref. 3), including a chronic toxicity 
study which identified a NOAEL (``No Observed Adverse Effect Level'') 
of 15,000 mg/kg bw/d of spirulina powder. Our review of the new 
information submitted by the petitioner, the information submitted in 
previously reviewed publications, as well as our own independent 
literature search and review of spirulina and phycocyanins, did not 
reveal any safety concerns relating to spirulina or phycocyanins, nor 
did it identify any information or data that would change the ADI of 
1.8 g/p/d for phycocyanins (Ref. 3).
    We discussed the potential allergenicity of spirulina phycocyanins 
in our final rule for the use of spirulina extract as a color additive 
in candy and chewing gum (78 FR 49117 at 49119, August 13, 2013). We 
stated that, based on our review of a comparison of the known amino 
acid sequences of c-phycocyanin, which is the predominant phycocyanin 
present in spirulina (Ref. 2), with the sequences of known protein 
allergens, there is a low probability that the spirulina c-phycocyanin 
is a protein allergen. Additionally, while allophycocyanin is present 
at very low levels in spirulina, we consider these levels and any 
allergenicity risk to be negligible. Therefore, we concluded that 
spirulina phycocyanins present an insignificant allergy risk to 
consumers of the color additive. In addition, after a review of all 
available literature relevant to the potential allergenicity of 
spirulina, we have determined that while spirulina extract and 
specifically c-phycocyanin are possible allergens for certain 
individuals, reactivity is not

[[Page 5294]]

widespread and spirulina sensitization appears to be rare (Ref. 3). 
Therefore, we continue to conclude that spirulina extract as a color 
additive presents an insignificant allergy risk for the general 
population (Ref. 3). We are not aware of any new information that would 
cause us to change this conclusion.
    Our review considered the safety data provided by the petitioner, 
including our independent review of the current published literature, 
which did not present evidence of safety concerns for spirulina extract 
at the expected dietary exposures. Given that the upper-bound 
cumulative dietary exposure estimate for c-phycocyanin of 1.14 g/p/d is 
not expected to increase with the new petitioned uses, exposure remains 
below the previously determined ADI for phycocyanins of 1.8 g/p/d. 
Therefore, we conclude that spirulina extract is safe for the 
petitioned uses (Refs. 2 and 3).

IV. Conclusion

    Based on the data and information in the petition and other 
available relevant information, we conclude that the petitioned use of 
spirulina extract as a color additive at levels consistent with GMP (in 
human foods generally except for infant formula and products subject to 
regulation by the USDA under the Federal Meat Inspection Act, the 
Poultry Products Inspection Act, or the Egg Products Inspection Act) is 
safe.
    We further conclude that this color additive will achieve its 
intended technical effect and is suitable for the petitioned use. 
Therefore, we are amending the color additive regulations in 21 CFR 
part 73 to provide for the safe use of this color additive as set forth 
in this document. In addition, based on the factors in 21 CFR 71.20(b) 
and consistent with our conclusions in our earlier published approvals 
of spirulina extract for petitioned uses, we continue to conclude that 
batch certification of spirulina extract is not necessary to protect 
the public health.

V. Public Disclosure

    In accordance with Sec.  71.15 (21 CFR 71.15), the petition and the 
documents that we considered and relied upon in reaching our decision 
to approve the petition will be made available for public disclosure 
(see FOR FURTHER INFORMATION CONTACT). As provided in Sec.  71.15, we 
will delete from the documents any materials that are not available for 
public disclosure.

VI. Analysis of Environmental Impact

    We previously considered the environmental effects of this order, 
as stated in the August 5, 2024, Federal Register notification of 
petition for CAP 4C0334 (89 FR 63330 at 63331). The petitioner claimed 
that this action is categorically excluded under Sec.  25.32(k) (21 CFR 
25.32(k)) because the substance is intended to be added directly to 
food, remain in food through ingestion by consumers, and is not 
intended to replace macronutrients in food. We have not received any 
new information or comments regarding this claim of categorical 
exclusion. We considered the petitioner's claim of categorical 
exclusion and determined that this action is categorically excluded 
under Sec.  25.32(k) (Ref. 4). Therefore, neither an environmental 
assessment nor an environmental impact statement is required.

VII. Paperwork Reduction Act of 1995

    This order contains no collection of information. Therefore, 
clearance by the Office of Management and Budget under the Paperwork 
Reduction Act of 1995 is not required.

VIII. Section 301(ll) of the FD&C Act

    Our review of this petition was limited to section 721 of the FD&C 
Act (21 U.S.C. 379e). This order is not a statement regarding 
compliance with other sections of the FD&C Act. For example, section 
301(ll) of the FD&C Act (21 U.S.C. 331(ll)) prohibits the introduction 
or delivery for introduction into interstate commerce of any food that 
contains a drug approved under section 505 of the FD&C Act (21 U.S.C. 
355), a biological product licensed under section 351 of the Public 
Health Service Act (42 U.S.C. 262), or a drug or biological product for 
which substantial clinical investigations have been instituted and 
their existence has been made public, unless one of the exemptions in 
section 301(ll)(1) to (4) of the FD&C Act applies. In our review of 
this petition, we did not consider whether section 301(ll) of the FD&C 
Act or any of its exemptions apply to food containing this color 
additive. Accordingly, this order should not be construed to be a 
statement that a food containing this color additive, if introduced or 
delivered for introduction into interstate commerce, would not violate 
section 301(ll) of the FD&C Act. Furthermore, this language is included 
in all color additive final orders that pertain to food and therefore 
should not be construed to be a statement of the likelihood that 
section 301(ll) of the FD&C Act applies.

IX. Objections

    This order is effective as shown in the DATES section, except as to 
any provisions that may be stayed by the filing of proper objections. 
If you will be adversely affected by one or more provisions of this 
regulation, you may file with the Dockets Management Staff (see 
ADDRESSES) either electronic or written objections. You must separately 
number each objection, and within each numbered objection you must 
specify with particularity the provision(s) to which you object, and 
the grounds for your objection. Within each numbered objection, you 
must specifically state whether you are requesting a hearing on the 
particular provision that you specify in that numbered objection. If 
you do not request a hearing for any particular objection, you waive 
the right to a hearing on that objection. If you request a hearing, 
your objection must include a detailed description and analysis of the 
specific factual information you intend to present in support of the 
objection in the event that a hearing is held. If you do not include 
such a description and analysis for any particular objection, you waive 
the right to a hearing on the objection.
    Any objections received in response to the regulation may be seen 
in the Dockets Management Staff between 9 a.m. and 4 p.m., Monday 
through Friday, and will be posted to the docket at https://www.regulations.gov. We will publish notice of the objections that we 
have received or lack thereof in the Federal Register.

X. References

    The following references are on display at the Dockets Management 
Staff (see ADDRESSES) and are available for viewing by interested 
persons between 9 a.m. and 4 p.m., Monday through Friday; they are also 
available electronically at https://www.regulations.gov.

1. Memorandum from N. Belai, Color Technology Branch, Division of 
Color Certification and Technology, Office of Cosmetics and Colors, 
Office of the Chief Scientist, FDA to M. Santos, Regulatory 
Management Branch (RMB), Division of Food Ingredients (DFI), Office 
of Pre-Market Additive Safety (OPMAS), Office of Food Chemical 
Safety, Dietary Supplements, and Innovation (OFCSDSI), Human Foods 
Program (HFP), FDA, February 3, 2026.
2. Memorandum from H. Lee, Chemistry Evaluation Branch, DFI, OPMAS, 
OFCSDSI, HFP, FDA to M. Santos, RMB, DFI, OPMAS, OFCSDSI, HFP, FDA, 
February 3, 2026.
3. Memorandum from R. Arechavala, Toxicology Review Branch, DFI, 
OPMAS, OFCSDSI, HFP, FDA to M. Santos, RMB, DFI, OPMAS, OFCSDSI, 
HFP, FDA, February 3, 2026.
4. Memorandum from A. Thompson-Woods, Environmental Review Team, 
OPMAS, OFCSDSI, HFP, FDA to M. Santos, RMB,

[[Page 5295]]

DFI, OPMAS, OFCSDSI, HFP, FDA, February 3, 2026.

List of Subjects in 21 CFR Part 73

    Color additives, Cosmetics, Drugs, Foods, Medical devices.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
the authority delegated to the Commissioner of Food and Drugs, 21 CFR 
part 73 is amended as follows:

PART 73--LISTING OF COLOR ADDITIVES EXEMPT FROM CERTIFICATION

0
1. The authority citation for part 73 continues to read as follows:

    Authority: 21 U.S.C. 321, 341, 342, 343, 348, 351, 352, 355, 
361, 362, 371, 379e.


Sec.  73.530  [Amended]

0
2. Section 73.530 is amended by revising paragraphs (b) and (c) to read 
as follows:


Sec.  73.530  Spirulina extract.

* * * * *
    (b) Specifications. Spirulina extract must conform to the following 
specifications and must be free from impurities, other than those 
named, to the extent that such other impurities may be avoided by good 
manufacturing practice:
    (1) Lead, not more than 0.2 milligrams per kilogram (mg/kg) (0.2 
parts per million (ppm));
    (2) Arsenic, not more than 0.3 mg/kg (0.3 ppm);
    (3) Mercury, not more than 0.1 mg/kg (0.1 ppm);
    (4) Cadmium, not more than 0.3 mg/kg (0.3 ppm); and
    (5) Negative for microcystin toxin.
    (c) Uses and restrictions. Spirulina extract may be safely used for 
coloring human foods generally at levels consistent with good 
manufacturing practice, except that it may not be used to color 
products that are subject to regulation by the U.S. Department of 
Agriculture under the Federal Meat Inspection Act (21 U.S.C. 601 et 
seq.), the Poultry Products Inspection Act (21 U.S.C. 451 et seq.), or 
the Egg Products Inspection Act (21 U.S.C. 1031 et seq.); infant 
formula; or foods for which standards of identity have been issued 
under section 401 of the Federal Food, Drug, and Cosmetic Act, unless 
the use of the added color is authorized by such standards.
* * * * *

Lowel M. Zeta,
Acting Deputy Commissioner for Policy, Legislation, and International 
Affairs.
[FR Doc. 2026-02314 Filed 2-5-26; 8:45 am]
BILLING CODE 4164-01-P